Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Drug helps young breast cancer patients avoid early menopause

09 March 2015

By Meghna Kataria

Appeared in BioNews 793

A drug can reduce the risk of infertility and early menopause in women undergoing chemotherapy for certain early stage breast cancers.

Supplementing chemotherapy with injections of a hormone-blocking drug, known as goserelin, significantly prevented failure of the ovaries and preserved fertility in women, according to the results of a phase III clinical trial published in The New England Journal of Medicine.

'Some of the most distressing side effects of chemotherapy in young women with breast cancer are early and sudden onset of menopause and infertility,' said Professor Kathy Albain, of Loyola University Chicago and a senior author on the study. 'We found that, in addition to reducing the risk of sudden, early menopause, and all of the symptoms that go along with menopause, goserelin was very safe and may even improve survival.'

With 1.7 million new cases in 2012, breast cancer is the most common cancer in women. Chemotherapy regimens include drugs such as cyclophosphamide (also used in the study), which damage the DNA of actively dividing cancer cells. However, these come with a downside in the form of collateral damage of ovarian cells - which precipitates early menopause and infertility. Concerns about these issues often factor into treatment decisions made by women.

Researchers studied 257 premenopausal women who were diagnosed with stage I to IIIA of a type of breast cancer that does not respond to hormones. Half of the women were randomly assigned to receive the chemotherapy drug cyclophosphamide along with injections of goserelin once every four weeks, whilst the rest received the chemotherapy drug alone. Two years later, 22 percent of women in the chemotherapy-alone group showed early menopause. They did not menstruate and had very low levels of fertility-associated hormones. However, only eight percent of women who received goserelin exhibited these symptoms.

Pregnancy rates showed the same trends - 21 percent of women in the goserelin group achieved at least one pregnancy versus 11 percent in the chemotherapy-alone group.

'Preserving ovarian function is a vital survivorship issue for young breast cancer patients. In addition to improving prospects for fertility, this intervention should help avoid a variety of unwanted effects of early menopause,' said Dr Halle Moore, lead investigator of the study and an oncologist at the Cleveland Clinic.

Goserelin is similar to hormones found in the body, and works by preventing the production of sex hormones. This causes the ovaries to temporarily enter an inactive state, thereby protecting the egg cells from any damage that chemotherapy can cause. The study included women with estrogen- and progesterone-receptor-negative breast cancer only.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

01 August 2016 - by Dr Roger Sturmey 
Reports that scientists in Greece have rejuvenated ovaries in perimenopausal women is potentially very exciting. However, there remain significant questions about this research...
23 November 2015 - by Dr Edgar Mocanu 
A recent study in mice raised the possibility of restoring ovarian function after chemotherapy. But before creating hype, the medical community has a duty to deliver evidence from human studies...
01 September 2015 - by Kirsty Oswald 
Researchers in the USA have found that fertility concerns may be contributing to low tamoxifen use and discontinuation of the drug among reproductive-age breast cancer patients...
10 August 2015 - by Dr Barbara Kramarz 
In this Radio 4 programme, Dr Aarathi Prasad investigates new research that is overturning decades-old assumptions about how human eggs are produced and what causes the menopause...
03 August 2015 - by Ruth Retassie 
Researchers have developed a mathematical model for determining what age women should start trying to conceive...

24 November 2014 - by Isobel Steer 
The majority of young breast cancer patients are not being referred for treatment which could preserve their fertility after chemotherapy, says a UK charity...
14 April 2014 - by Cait McDonagh 
A Crohn's disease patient is challenging a decision to refuse her funding for her eggs to be cryopreserved before she undergoes a bone marrow transplant and chemotherapy...
29 July 2013 - by Dr James Heather 
Despite treatment for childhood cancer causing an increased risk of infertility, most women still manage to conceive, research has shown...
08 April 2013 - by Cait McDonagh 
An experimental preservation method could let women store eggs at home as a powder and then ‘just add water’ (and sperm) when needed...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation